Abstracts Archive - Page 3 of 2607 - ACR Meeting Abstracts

Abstract Number: 0012 • ACR Convergence 2025
KT501, a CD19/BCMA/CD3 trispecific antibody, leads to rapid and deep B-cell depletion with well-tolerated safety
Min Bao, John Wang, Jay Zhao and Weihao Xu, Kali Therapeutics, San Mateo, CA
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 or B-cell maturation antigen (BCMA) have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic…
Abstract Number: 0019 • ACR Convergence 2025
Single cell characterization of the circulating immune system in Sjögren’s Syndrome
Alejandro Gómez Gómez¹, Héctor Corominas², Rosario Garcia Vicuña³, Mercedes Freire González⁴, Sheila Melchor-Díaz⁵, Paloma Vela Casasempere⁶, Paula Estrada-Alarcón⁷, Jose Luis Tandaipan⁸, Monica Fernandez Castro⁹, Sara Maria Rojas Herrera¹⁰, Marina Rodríguez López¹¹, Beatriz Paredes-Romero¹², Santiago Muñoz¹³, Marta López¹⁴, Ignacio Braña¹⁵, Gema Bonilla¹⁶, Raúl Menor Almagro¹⁷, Sara Manrique-Arija¹⁸, Mª Angeles Blazquez Cañamero¹⁹, Lilian López-Núñez²⁰, Carles Galisteo Veiga²¹, Juan José Alegre-Sancho²², Jose Rosas Gómez de Salazar²³, Jose Javier Pérez Venegas²⁴, Judit Font-Urgelles²⁵, José Andrés Román Ivorra²⁶, José Miguel Sequí-Sabater²⁷, Rafaela Ortega-Castro²⁸, Clara Moriano²⁹, Guadalupe Manzano-Canabal³⁰, Cilia Peralta-Ginés³¹, Javier Narváez³², Rafael Cáliz-Cáliz³³, Javier Martínez-Ferrin³⁴, Lara Sánchez Bilbao³⁵, Belén Serrano-Benavente³⁶, Natalia Boix- Martí³⁷, Ares Selles-Rius³⁸, Maribel Pérez³⁹, Juan Cañete⁴⁰, Núria Palau Balaña³⁸, Damiana Alvarez Errico³⁹, Yolanda Guillén⁴¹, Juan Ángel Patiño Galindo⁴¹, Antonio Julià¹, Sara Marsal Barril⁴² and Jose Luis Andreu⁴³, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²Hospital de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Barcelona, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴⁴ Hospital Universitario A Coruña, Rheumatology, A Coruña, La coruna, Spain, ⁵Hospital Universitario ¹² de Octubre, Rheumatology, Madrid, Madrid, ⁶Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ⁷Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁸Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ¹⁰Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ¹¹Complejo Hospitalario Universitario de Santiago, Rheumatology, Santiago de Compostela., Santiago de Compostela, Spain, ¹²Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ¹³Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁴Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁵Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹⁷Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ¹⁸Hospital Regional Universitario Málaga, Malaga, Spain, ¹⁹Hospital Ramon y Cajal, Madrid, Spain, ²⁰Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Palma de Mallorca, Spain, ²¹Hospital Parc Taulí, Rheumatology, Sabadell, Sabadell, Spain, ²²Hospital Universitario Doctor Peset, Valencia, Spain, ²³Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁴Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²⁷Hospital Universitario La Fe (Valencia), Valencia, Spain, ²⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ²⁹Hospital León, LEON, Castilla y Leon, Spain, ³⁰Hospital Virgen de la Concha (Zamora), Zamora, Spain, ³¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³²Hospital Universitario de Bellvitge, Barcelona, Spain, ³³Hospital Universitario Virgen de las Nieves, Rheumatology, Granada, Granada, Spain, ³⁴Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Murcia, Spain, ³⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³⁶Hospital Gregorio Marañon, Madrid, Spain, ³⁷Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, ³⁸Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain, ³⁹IMIDomics, Barcelona, Barcelona, Spain, ⁴⁰Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴¹IMIDomics, Barcelona, Spain, ⁴²Vall Hebron Hospital Research Institute, Barcelona, Spain, ⁴³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by the infiltration of circulating immune cells into the salivary and lacrimal glands. The properties…
Abstract Number: 0027 • ACR Convergence 2025
Consistent Method to Generate Hyaline Cartilage from Human Induced Pluripotent Stem Cell-Derived Multi-Tissue Organoids
Huzefa Husain¹, Manci Li², Juan Abrahante³, Natalia Mancipe³, Amanda Vegoe⁴, Yi Wen Chai⁵, Beth Lindborg⁶, Marc Tompkins⁷, Brenda Ogle⁸, Peter Larsen⁹, Timothy O'Brien¹⁰ and Ferenc Tóth¹¹, ¹Department of Biomedical Engineering, University of Minnesota, Minneapolis, ²Department of Electrical and Computer Engineering, Minnesota Center for Prion Research and Outreach, University of Minnesota, Minneapolis, ³Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, ⁴Department of Veterinary Population Medicine and Stem Cell Institute, University of Minnesota, Sarcio, Inc, St. Paul, ⁵Stem Cell Institute, University of Minnesota, Minneapolis, ⁶Sarcio, Inc., St. Paul, ⁷Department of Orthopedic Surgery, University of Minnesota, Sarcio, Inc., Minneapolis, ⁸Department of Biomedical Engineering, Stem Cell Institute, University of Minnesota, Minneapolis, ⁹Department of Veterinary and Biomedical Sciences, Minnesota Center for Prion Research and Outreach, University of Minnesota, St. Paul, ¹⁰Department of Veterinary Population Medicine and Stem Cell Institute, University of Minnesota, Sarcio, Inc, Minneapolis, ¹¹Department of Veterinary Clinical Sciences, University of Minnesota, St. Paul
Background/Purpose: Existing methods to produce hyaline cartilage from human induced pluripotent stem cells (hiPSCs) face significant limitations, such as complex culture conditions, instability of the…
Abstract Number: 0028 • ACR Convergence 2025
Computational and Laboratory Identification of Risk-Driving Alleles on Juvenile Idiopathic Arthritis (JIA)-Associated Haplotypes
Adam He¹, Hannah Ainsworth², Kaiyu Jiang³, Ekaterina Khtovatkova², Yanmin Chen³, Carl Langefeld⁴, Charles G Danko¹ and James N. Jarvis⁵, ¹Cornell University Baker School of Veterinary Medicine, Ithaca, NY, ²Wake Forest University, Winston-Salem, NC, ³University of Washington School of Medicine, Seattle, WA, ⁴Wake Forest University School of Medicine, Winston Salem, NC, ⁵University of Washington Center for Indigenous Health, Seattle, WA
Background/Purpose: Multiple genomic regions are known to confer risk for JIA. However, identifying the SNPs that exert the biological effects that confer risk, and therefore…
Abstract Number: 0006 • ACR Convergence 2025
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
Abstract Number: 0003 • ACR Convergence 2025
In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
Xiaoyu Pan¹, Xiaoning Wang¹, Zhihao Chen¹, Xiaowen Zou¹, Siqi Li¹, Jian Ye¹, Fei Lin¹, Yang He¹, Edo Kon², Peng Zhu¹, Mengyun Chen¹ and Weiyi Zhang¹, ¹RiboX Therapeutics, Shanghai, China (People's Republic), ²RiboX Therapeutics, Cambridge, MA
Background/Purpose: Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized cancer treatment and shown promise in addressing autoimmune diseases. However, current ex vivo CAR T-cell therapies…
Abstract Number: 0013 • ACR Convergence 2025
Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
Xiaofeng Zhao¹, Xiaoqing Liu¹, Yuxi Yan², Tiezheng Liu³, Yong Fu³, Yulan Hu², Kangmin Zhou², Minyun Zhou⁴, Yingying Hu² and Shunwei Zhu², ¹State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing
Background/Purpose: B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that contributes to the regulation of T cell, B cell and dendritic cell…
Abstract Number: 0025 • ACR Convergence 2025
Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Elio Carmona¹, Rabia Deniz², Cemal Bes³, Haner Direskeneli⁴, Ahmet Gul⁵ and Amr Sawalha⁶, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ³University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ⁴Marmara University, ISTANBUL, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing inflammatory disease characterized by complex immunopathogenesis and limited treatment options. Monocytes are known to play a significant…
Abstract Number: 0020 • ACR Convergence 2025
Bulk RNA-sequencing of Leukocytoclastic Vasculitis Skin Biopsies Show Upregulation of Leukocyte Migration Genes
Anne Carlton, Lam Tsoi, Joseph Kirma, Jennifer Fox, Paul Harms and Johann Gudjonsson, University of Michigan, Ann Arbor, MI
Background/Purpose: Vasculitis encompasses multiple conditions united by end-organ damage due to an immune-mediated reaction against the vasculature. Leukocytoclastic vasculitis (LCV) is a subtype of cutaneous…
Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Philipp Richle, Stephanie Jungmichel, Alessio Vantellini, André Fonseca, Anna Howald, Fabian Scheifele, Loredana iuliano, Ariadna Vilarrasa, Romina Doerig, Hannes Merten, Philip Knobel, Daniel Lenherr-Frey, Christian Leisner and Leonardo Borras, CDR-Life, Horgen, Zurich, Switzerland
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…
Abstract Number: 0023 • ACR Convergence 2025
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Benjamin Jones¹, Miles Smith², Rufei Lu², Carla Guthridge², Susan Macwana², Wade DeJager³, Nancy Olsen⁴, Catriona Wagner⁵, Judith James², David Karp⁶ and Joel Guthridge², ¹Oklahoma State University, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁶UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Hydroxychloroquine (HCQ) is routinely prescribed for treatment of systemic lupus erythematosus (SLE) due to its efficacy at decreasing disease activity/SLE flares and strong benefit:risk…
Abstract Number: 0022 • ACR Convergence 2025
Genome-wide association study identifies novel genetic risk factors for rheumatoid arthritis-associated interstitial lung disease
Austin Wheeler¹, Thomas Riley², Riku Takei³, Joshua Baker², Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, Grant Cannon⁶, Gary Kunkel⁷, Gail Kerr⁸, Dana Ascherman⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Jill Poole¹, Ted Mikuls¹, Tony Merriman¹² and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Interstitial lung disease (ILD) is clinically present in ~10% of individuals with RA. There is recognized overlap between RA-ILD and idiopathic pulmonary fibrosis (IPF)…
Abstract Number: 0009 • ACR Convergence 2025
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Adam Cartwright¹, Lucas Gyger¹, Foram Desai², Shailee Vora², Anna Kostikova¹, Xudong Wang², Peter Trenh², Katie May², Sophia Nguyen², Chris King², Daniel Lam², Xavi Lucas¹, Mary Zlotosch², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Debora Bonenfant¹, Sharon Townson², Eswar Krishnan², Filip Janku², John Castle¹, Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1, an immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein, plays a critical role in mediating T- and B-cell receptor activity.…
Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…
Abstract Number: 0007 • ACR Convergence 2025
WITHDRAWN

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].